Schéma : The main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. In this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.


Core study therapy
idarubicin for both induction and consolidation courses
if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)


Current primary outcome:
cumulative incidence of failures [ Time Frame: 9 months ]
failures include:
* resistant disease defined according to the IWG AML response criteria
* hypoplastic marrow after D42 and absence of myeloidrecovery
* early relapse up to 9 months from CR : Either AML relapse as in the IWG classification or MDS relapse

Current secondary outcome:
- response rate [ Time Frame: 9 months ]
- relapse rate [ Time Frame: within 2 years after inclusion ]
Either AML relapse as in the IWG classification - Or MDS relapse defined for this study as follows: (i) Persistent cytopenias, if unexplained by other cause, and (ii) myelodysplastic marrow with less than 20% marrow blasts in two samples taken 3 months apart
- overall survival [ Time Frame: within 2 years after inclusion ]
- adverse events [ Time Frame: within 2 years after inclusion ]